How Advanced Wound Dressings Are Changing Chronic Wound Care

A chronic wound is one that fails to heal in the expected time. Diabetic foot ulcers, pressure ulcers, and venous leg ulcers are common examples. These wounds often stay open for weeks or months. A single patient can therefore need many dressings over one course of care.

The cost is large. A study in Value in Health analysed 2014 Medicare data and found that 8.2 million beneficiaries, nearly 15%, had at least one wound or infection. The authors estimated total Medicare spending on wound care at between USD 28.1 billion and USD 96.8 billion, depending on the method used.

An ageing population adds pressure. The NMSC report cites WHO figures showing that people aged 65 and over will grow from 1 billion in 2020 to 1.4 billion in 2030. Older adults often live with several chronic conditions at once, and that raises the odds of a wound that heals slowly.

Diabetes is the other major driver. WHO reports that the number of people with diabetes rose from 200 million in 1990 to about 830 million in 2022. WHO also lists foot ulcers and lower limb amputation among the complications that can follow. Better wound care is one way health systems try to prevent that outcome.

Acute and chronic wounds also behave differently. Most acute wounds, such as a clean surgical incision, heal in a predictable way and need dressings for a short time. Chronic wounds do not follow that path. They stall, and each stalled wound keeps generating demand for dressings, nursing time, and follow-up visits.

NMSC segments the market by wound type into surgical and traumatic wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and burns and other wounds. It also splits applications into acute and chronic wounds. Each group places different demands on a dressing.

Surgical wounds and diabetic foot ulcers. In the Medicare study, surgical wounds were the costliest category, with estimates from USD 11.7 billion to USD 38.3 billion. Diabetic foot ulcers followed at USD 6.2 billion to USD 18.7 billion. Both figures include the cost of infection.

Pressure ulcers. The U.S. Agency for Healthcare Research and Quality counted 503,300 hospital stays in 2006 that noted a pressure ulcer diagnosis. Adult stays with the diagnosis cost USD 11.0 billion that year. The data are dated, yet they show how heavily pressure injuries weigh on hospitals.

Venous leg ulcers, burns and other wounds. Venous leg ulcers often produce a lot of fluid, so absorbency matters. Burns need dressings that protect fragile tissue and manage moisture. Clinicians match the dressing to the wound rather than the other way round.

Traditional gauze simply covers a wound. Advanced dressings try to shape the wound environment. They balance moisture, manage exudate, support wound bed preparation, and help lower infection risk. The NMSC report lists foam, hydrocolloid, film, collagen, wound contact layer, superabsorbent, and alginate dressings in its segmentation, and its market definition also covers hydrogel dressings and antimicrobial dressings.

The evidence deserves honesty here. A 2015 Cochrane overview of dressings for foot ulcers in people with diabetes found no strong evidence of differences between dressing types. It also found no clear proof that advanced dressings healed ulcers better than basic contact dressings. The authors suggested that unit cost, handling, and patient comfort should guide choice until stronger trials appear. That context helps explain why cost and clinical evidence both shape purchasing.

Infection control deserves a closer look. A wound that turns infected can heal more slowly and may need stronger treatment. That is why antimicrobial dressings, which release or hold agents that act on bacteria, form a distinct group. Clinicians still have to judge when a wound truly needs one, since overuse carries its own risks.

NMSC estimates the market at USD 10.66 billion in 2023 and forecasts USD 17.21 billion in 2030. The projected CAGR is 7.1% across 2024 to 2030. The table below sets out the headline figures.

Definitions matter when comparing numbers. NMSC segments the market by product into dressings, devices and accessories such as negative pressure wound therapy, and grafts and matrices. Other publishers draw the line differently. The broader wound care market covers a wider set of products, so figures from different reports should not be placed side by side without checking scope.

A 7.1% CAGR is steady rather than explosive. It suggests a market built on persistent clinical need rather than a single breakthrough product. Growth of that kind usually depends on how many patients present with hard-to-heal wounds, and on whether health systems are willing to pay for better dressings.

Drivers. Ageing populations, rising chronic disease, and better dressing technology push the market forward. NMSC points to smart dressings as one example of technology improving the clinical offer. Each factor raises either the number of wounds or the tools available to treat them.

Restraints. Cost is the main brake. Advanced dressings cost more than basic ones, and that limits use in budget-constrained settings. The Cochrane finding adds a second brake, because payers may ask for stronger proof before paying more.

Opportunities. Digital health may open a new path. NMSC highlights sensor-enabled dressings that send real-time healing data. Products in the smart bandage market point in the same direction, since early signs of infection or poor healing could trigger faster care.

For manufacturers, the practical lesson is to pair product innovation with outcome data. For hospitals and clinics, it is to track the cost of a dressing against the cost of a wound that stays open. Both groups face the same question, which is whether better dressings save time and complications further down the line.

NMSC describes North America as the dominant region, although the report gives no share percentage. It cites U.S. adults aged 65 and over rising from 58 million in 2022 to 82 million by 2050. It also cites Canadian diabetes cases rising from 2.9 million in 2021 to 3.3 million by 2030.

Asia-Pacific shows a steady rise. The report notes that health spending per person in South Korea reached USD 4,946 in 2022, up from USD 3,546 in 2019. Higher spending can widen access to newer products, though the report does not size the regional market.

Care settings are also shifting. NMSC lists hospitals, home healthcare, clinics, and other settings as end users. As more wound care moves out of hospitals, growth in home healthcare services may raise demand for dressings that patients and carers can manage with less training.

The NMSC report tracks several launches. In September 2024, Solventum launched the V.A.C. Peel and Place Dressing for negative pressure wound therapy. In June 2023, Evonik’s JeNaCell introduced epicite balance for chronic wounds with low to medium exudate. Both show manufacturers tailoring products to specific wound conditions rather than selling one dressing for every case.

Launches like these matter because they reflect where clinical needs are specific. A dressing built for low to medium exudate suits a different patient from one built for negative pressure therapy. Buyers who follow such product changes can match supply to the wound types they treat most often.